Cargando…

Does Gender Influence the Cardiovascular Benefits Observed with Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors? A Meta-Regression Analysis

INTRODUCTION: Although a large recent trial had shown improved cardiovascular outcomes of diabetic patients on sodium glucose co-transporter-2 (SGLT-2) inhibitors, the influence of gender differences on such outcomes is not known. Thus, we aimed to assess the impact of gender on such outcomes in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahmoud, Ahmed N., Elgendy, Islam Y., Saad, Marwan, Elgendy, Akram Y., Barakat, Amr F., Mentias, Amgad, Abuzaid, Ahmed, Bavry, Anthony A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446808/ https://www.ncbi.nlm.nih.gov/pubmed/27896705 http://dx.doi.org/10.1007/s40119-016-0075-1

Ejemplares similares

Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials
por: Barakat, Amr F, et al.
Publicado: (2017)

Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects
por: Mahmoud, Ahmed N, et al.
Publicado: (2018)

Losartan for Preventing Aortic Root Dilatation in Patients with Marfan Syndrome: A Meta-Analysis of Randomized Trials
por: Elbadawi, Ayman, et al.
Publicado: (2019)

Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials
por: Mahmoud, Ahmed N., et al.
Publicado: (2017)

The Landscape of Medical Literature in the Era of COVID-19: Original Research Versus Opinion Pieces
por: Elgendy, Akram Y., et al.
Publicado: (2020)

The Impact of Fractional Flow Reserve on Revascularization
por: Elgendy, Islam Y., et al.
Publicado: (2015)

From CoreValve to Evolut PRO: Reviewing the Journey of Self-Expanding Transcatheter Aortic Valves
por: Mahtta, Dhruv, et al.
Publicado: (2017)

Cardiovascular Abnormalities and in-Hospital All-Cause Mortality in Patients with Spontaneous Sub-Arachnoid Hemorrhage: An Observational Study
por: Mahmoud, Ahmed N., et al.
Publicado: (2016)

Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials
por: Bavry, Anthony A., et al.
Publicado: (2015)

Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial
por: Elbadawi, Ayman, et al.
Publicado: (2016)

Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study)
por: Bavry, Anthony A., et al.
Publicado: (2017)

Erratum to: Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study)
por: Bavry, Anthony A., et al.
Publicado: (2017)

Sex and gender differences in COVID-19: More to be learned!()
por: Ya'qoub, Lina, et al.
Publicado: (2021)

Safety of Routine Invasive Versus Selective Invasive Therapy in Women with Non-ST-Elevation Acute Coronary Syndrome
por: Bavry, Anthony A., et al.
Publicado: (2015)

Early Invasive Strategy and In‐Hospital Survival Among Diabetics With Non‐ST‐Elevation Acute Coronary Syndromes: A Contemporary National Insight
por: Mahmoud, Ahmed N., et al.
Publicado: (2017)

Impact of COVID-19 on Management Strategies for Coronary and Structural Heart Disease Interventions
por: Ya’Qoub, Lina, et al.
Publicado: (2022)

Clinical and Angiographic Outcomes With Drug‐Coated Balloons for De Novo Coronary Lesions: A Meta‐Analysis of Randomized Clinical Trials
por: Elgendy, Islam Y., et al.
Publicado: (2020)

A systematic bias assessment of top-cited full-length original clinical investigations related to COVID-19
por: Elgendy, Islam Y., et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)

Reply to “Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link”
por: Elgendy, Islam Y., et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Prevalence, Causes, and Predictors of 30‐Day Readmissions Following Hospitalization With Acute Myocardial Infarction Complicated By Cardiogenic Shock: Findings From the 2013–2014 National Readmissions Database
por: Mahmoud, Ahmed N., et al.
Publicado: (2018)

Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus
por: Rehman, Saad U, et al.
Publicado: (2020)

Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: Insights from a British cardiac center()
por: Abdelaziz, Hesham K., et al.
Publicado: (2020)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Characteristics and outcomes of COVID-19-associated pulmonary embolism
por: Sedhom, Ramy, et al.
Publicado: (2023)

When Ablation Is Not the Answer: Acute Left Main Thrombosis Causing Incessant Ventricular Tachycardia Following Left Ventricular Assist Device Implant
por: Mojadidi, Mohammad K, et al.
Publicado: (2017)

A rare cause of hypocalcemia
por: Elgendy, Islam Y., et al.
Publicado: (2013)

What is the Real Message of the ISCHEMIA Trial from a Clinician’s Perspective?
por: Elgendy, Islam Y, et al.
Publicado: (2020)

Why are women better protected from COVID-19: Clues for men? Sex and COVID-19
por: Elgendy, Islam Y., et al.
Publicado: (2020)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

Comparative Outcomes of Transapical Versus Transfemoral Access for Transcatheter Aortic Valve Replacement in Diabetics
por: Elbadawi, Ayman, et al.
Publicado: (2019)

Cardiogenic shock in the setting of acute myocardial infarction: Another area of sex disparity?
por: Bukhari, Syed, et al.
Publicado: (2021)

Thrombus Aspiration: Is It the Art or the Science?
por: Gilani, Syed, et al.
Publicado: (2021)

Invasive Management for Non–ST‐Segment–Elevation Myocardial Infarction and Chronic Kidney Disease: Does One Size Fit All?
por: Elbadawi, Ayman, et al.
Publicado: (2022)

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
por: Lopaschuk, Gary D., et al.
Publicado: (2020)

Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management
por: Fatima, Aroob, et al.
Publicado: (2023)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ird495k3j8l0srbt155a46f8r5